Progesterone Market Size & Share 2026-2035

Progesterone Market Size

The global progesterone market was valued at approximately USD 2.2 billion in 2025. The market size is projected to grow from USD 2.4 billion in 2026 to USD 5.4 billion by 2035, expanding at a CAGR of nearly 9.3% during the forecast period, according to the latest report published by Global Market Insights Inc.

Market growth is primarily driven by the increasing prevalence of hormonal disorders, rising adoption of hormone replacement therapy (HRT), growing infertility treatment rates, and expanding awareness regarding women’s reproductive health.

Progesterone is a naturally occurring steroid hormone widely utilized in pharmaceutical formulations to regulate menstrual cycles, support pregnancy, reduce risks associated with recurrent miscarriage and preterm birth, and manage menopausal symptoms. Progesterone is widely used in infertility management, assisted reproductive technologies (ART), contraception, prevention of preterm birth, and menopausal hormone therapy, making it an essential therapeutic hormone across gynecology and reproductive medicine.

Key companies operating in the market include Pfizer, Merck & Co., AbbVie, Ferring Pharmaceuticals, and Besins Healthcare. These players are actively involved in product innovation, regulatory approvals, expansion of fertility treatment portfolios, and strategic collaborations with reproductive healthcare providers to strengthen their market presence.

Between 2022 and 2024, the progesterone market experienced notable growth, increasing from approximately USD 1.8 billion in 2022 to nearly USD 2.1 billion in 2024. This growth was primarily supported by rising IVF procedure volumes, increasing diagnosis of hormonal deficiencies, greater awareness of menopause management, and growing acceptance of hormone replacement therapy. Additionally, expanding healthcare access in emerging economies, increasing investments in women’s health, rising maternal healthcare expenditure, and the growing availability of generic progesterone formulations significantly contributed to market expansion during this period.

The increasing global burden of menopausal and reproductive health conditions continues to support demand for progesterone therapies. According to the World Health Organization (WHO) Menopause Fact Sheet, the global population of women aged 50 years and above has increased significantly, with women over 50 accounting for nearly 26% of the global female population in recent years.

Additionally, WHO estimates indicate that infertility affects millions of reproductive-age individuals worldwide, accelerating demand for fertility-supportive hormonal therapies, including progesterone supplementation. The growing utilization of assisted reproductive technologies such as IVF and embryo transfer procedures has substantially increased the use of micronized progesterone injections, gels, capsules, and vaginal formulations globally.

Moreover, the increasing incidence of hormonal disorders such as polycystic ovary syndrome (PCOS) and endometriosis further increases the demand for hormone replacement therapies (HRT). For instance, as per the WHO, endometriosis affects roughly 10% (190 million) of reproductive-age women and girls globally. Similarly, as per the Office on Women's Health (OASH), more than 11% of American women between 15 and 44 are affected by endometriosis. Such a high occurrence of hormone disorders is driving the demand for progesterone-based therapies.

Progesterone Market Trends

The progesterone industry is witnessing rapid growth supported by the rising global burden of infertility and delayed pregnancies.

• According to the World Health Organization (WHO) 2023 report, approximately 17.5%, that is, roughly 1 in 6 people globally, experience infertility during their lifetime. Additionally, increasing maternal age and lifestyle-related reproductive disorders such as polycystic ovary syndrome (PCOS) are significantly increasing the demand for progesterone supplementation in assisted reproductive technologies (ART), including IVF and embryo transfer procedures. Thus, growing utilization of fertility preservation and reproductive support therapies continues to strengthen progesterone demand globally.

• In addition, the increasing menopausal population and growing awareness regarding menopause management are further contributing to market growth. For instance, because of rising life expectancy, by the year 2030, the global population of menopausal women is expected to include 1.2 billion people. Since progesterone is widely used in combination hormone replacement therapies to reduce endometrial cancer risk associated with estrogen therapy, the expanding menopausal population is creating sustained long-term demand for progesterone products.
• The market is also experiencing significant growth due to the expansion of fertility clinics and assisted reproductive technology centers globally. Based on ESHRE EIM Consortium data, roughly 4 million ART cycles are estimated annually worldwide. In 2021, a total of 1,103,633 ART treatment cycles were reported by 1,382 clinics across 37 European countries, a 20% increase from the 919,364 cycles reported in 2020.
• This rising accessibility to fertility services, increasing insurance coverage for infertility treatment in developed countries, and improving reproductive healthcare infrastructure in emerging economies are supporting higher adoption of progesterone therapies.
• Lastly, increasing investments in women’s health research and favorable regulatory support for reproductive healthcare products are strengthening the competitive landscape. Governments and healthcare organizations across several countries are expanding maternal health initiatives, infertility awareness programs, and reimbursement support for fertility treatments, thus boosting market growth.
• However, side effects and safety concerns represent significant restraint on the progesterone market. These side effects range from mild symptoms such as nausea, headaches, and breast tenderness to more severe complications like blood clots and mood changes.
• Additionally, safety concerns regarding long-term use and potential risks, particularly in specific patient populations such as pregnant women or individuals with certain medical conditions, may hamper adoption rates, thereby hindering the market growth to some extent.

Progesterone Market Analysis

Based on the formulation, the progesterone market is classified into natural and synthetic. The synthetic segment dominated the market in 2025 with a revenue of USD 1.4 billion and is anticipated to witness growth at a CAGR of 9.5% over the analysis period.

• The significant market share of synthetic progesterone formulations can be attributed to the widespread use of synthetic progestins in oral contraceptives, hormone replacement therapy (HRT), infertility treatment and gynecological disorder management.
• Synthetic progesterone formulations are highly stable, have a long shelf life, are inexpensive and have been used clinically for many years. These characteristics continue to drive their widespread use in both developed and emerging healthcare markets.
• Furthermore, the wide availability of generic synthetic hormone products and their incorporation in various combination therapies have further bolstered segment growth.
• The natural segment, on the other hand, held a market share of 36.6% in 2025.
• The bio-identical nature of natural progesterone mimics the progesterone produced by the human body, making it a preferred choice for many patients seeking hormone replacement therapy.
• Further, natural progesterone is often perceived as a safer option, particularly among women during pregnancy, as it is believed to carry a lower risk of adverse effects compared to synthetic versions.

Based on the route of administration, the progesterone market is classified into injectable, oral, transdermal, and other routes of administration. The oral segment held the largest market share of 52.5% in 2025.

• Oral progesterone formulations are widely used owing to the convenience offered and high physician preference, supported by the extensive adoption of oral therapies in hormone replacement therapy (HRT), infertility management, menstrual disorders, and pregnancy support treatments.
• The increasing use of oral progesterone formulations is due to ease of administration, better patient compliance and increasing availability of sustained-release technologies that enhance bioavailability and therapeutic efficacy.
• Furthermore, the growing use of oral progesterone capsules among menopausal women using bioidentical hormone replacement therapy has been a major driver of the drug’s global demand.
• The development of oral sustained-release formulations and micronization technologies has further improved absorption profiles and reduced dosing frequency, making oral progesterone a preferred therapeutic option across multiple indications in reproductive health.
• The injectable progesterone segment accounted for the second-highest share of 21.9% in 2025 owing to its extensive use in fertility treatments, assisted reproductive technologies (ART), and high-risk pregnancy management.
• Injectable progesterone formulations are widely preferred due to their rapid absorption, reliable therapeutic levels, and high clinical efficacy. Furthermore, advancements in long-acting and subcutaneous injectable progesterone formulations are improving patient convenience and treatment adherence, further contributing to segment growth.

Based on application, the progesterone market is segmented into menopause, contraception, dysfunctional uterine bleeding, hyperplastic precursor lesions, endometrial cancer, and other applications. The menopause segment dominated the market in 2025 and is expected to reach USD 1.7 billion by the end of the forecast period.

• The dominance of this segment is primarily driven by the rising global menopausal population and the increasing adoption of hormone replacement therapy (HRT) to treat conditions related to menopause such as hot flashes, mood disorders, sleep disturbances, vaginal atrophy, and osteoporosis risk.
• In combination HRT regimens, particularly in women with an intact uterus, progesterone is an important part of the therapy to reduce the risk of endometrial hyperplasia and endometrial cancer associated with estrogen therapy.
• Further, rising awareness about women’s hormonal health, increasing healthcare visits for managing menopausal symptoms, and growing acceptance of bioidentical hormone therapies are majorly propelling the growth of the segment.
• The contraception segment is anticipated to witness significant growth at a CAGR of 9.7% in the global progesterone market over the forecast period due to the increasing demand for effective hormonal birth control methods and rising awareness regarding family planning. Growing government initiatives promoting reproductive health and expanding access to contraceptive products, particularly in emerging economies, are supporting the high segmental growth.

Based on drug type, the progesterone market is bifurcated into branded and generic. The branded segment dominated the market in 2025 and is anticipated to grow at a CAGR of 9.2% between 2026 - 2035.

• Branded formulations benefit from strong brand recognition and trust among healthcare professionals and patients. Established brands are associated with quality, safety, and efficacy, influencing prescribing practices and patient preferences.
• Further, physicians have established preferences for certain branded products based on their experiences, perceptions of efficacy, and familiarity with the brand.
• Thus, physician habits and prescribing patterns contribute to the sustained use of branded drugs, thereby boosting the segmental growth.
• On the other hand, generic progesterone formulations are witnessing high adoption and were valued at USD 746.7 million in 2025, owing to their widespread availability and cost-effectiveness. Increasing patent expirations of branded hormone therapies and strong demand for affordable treatment options, particularly in emerging markets, will continue to support segment growth over the analysis timeframe.

Based on type, the progesterone market is classified into prescription and OTC. The prescription segment dominated the market in 2025 with a revenue of USD 1.6 billion.

• The prescription segment dominated the market in 2025 owing to the extensive clinical use of progesterone therapies in fertility treatment, hormone replacement therapy (HRT), pregnancy support, menstrual disorders, and gynecological conditions that require physician supervision and individualized dosing.
• Most progesterone products, particularly oral micronized capsules, injectables, vaginal gels, and sustained-release formulations, are regulated as prescription medications due to their hormonal effects and the need for careful monitoring of treatment duration, dosage, and patient response.
• In addition, favorable reimbursement coverage for prescription fertility and menopausal therapies in developed markets has further strengthened segment growth.
• The OTC segment was valued at USD 609 million in 2025 and is expected to grow at a CAGR of 9% due to increasing consumer awareness regarding hormonal health and the rising availability of over-the-counter progesterone creams and wellness products. The expanding online retail sector and increasing preference for convenient access to hormonal wellness products are contributing to segment growth.

Based on the distribution channel, the progesterone market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment dominated the market in 2025.

• Hospital pharmacies account for a significant market share of the market, given the clinical nature of progesterone therapies. Infertility treatment, high-risk pregnancy management, and hormone replacement therapy all require physician oversight, thus concentrating prescribing and dispensing activity within hospital and fertility care settings.
• Further, hospitals serve as the primary point of care for women presenting with pregnancy complications, recurrent miscarriage, preterm labor risk, and acute menopausal conditions, thus increasing the patient flow in hospital pharmacies.
• Lastly, rapid expansion of fertility centers and multispecialty maternity hospitals in emerging markets has broadened the hospital pharmacy network, further reinforcing the segmental growth.
• The online pharmacies segment is expected to grow at a CAGR of 9.9% over the forecast years owing to the increasing adoption of digital healthcare platforms and rising consumer preference for convenient medication access. Growing availability of prescription progesterone products through e-pharmacy platforms, coupled with expanding teleconsultation services and home delivery options, is supporting segment growth.

North America Progesterone Market

The North America progesterone industry dominated the market with a market share of approximately 37.8% in 2025.

• North America, particularly the U.S. holds a leading position in the market owing to the high adoption of hormone replacement therapy (HRT), increasing infertility treatment rates, and strong awareness regarding women’s reproductive health.
• The U.S. progesterone market was valued at USD 639.3 million and USD 675.3 million in 2022 and 2023, respectively. The market size reached approximately USD 769.8 million in 2025, growing from USD 719 million in 2024.
• The growth of the U.S. market is primarily driven by the increasing prevalence of infertility, rising maternal age, and the growing adoption of hormone replacement therapy among menopausal women.
• As per the National Institute on Aging, millions of women in the U.S. enter menopause annually, creating sustained long-term demand for progesterone-based HRT products. Further, according to the Centers for Disease Control and Prevention (CDC), more than 389,000 ART cycles were performed in the U.S. in recent years, highlighting the strong demand for fertility-supportive hormonal therapies, including progesterone.
• Additionally, the increasing number of IVF and embryo transfer procedures performed across fertility clinics continues to support strong progesterone prescription volumes for luteal phase support therapies.
• Further, continuous advancements in oral micronized progesterone formulations, strong physician awareness, and increasing acceptance of bioidentical hormone therapies continue to reinforce the upward growth trajectory of the U.S. market.

Europe Progesterone Market

Europe progesterone industry accounted for USD 620.4 million in 2025 and is anticipated to witness substantial growth over the forecast period.

• The increasing aging female population and rising adoption of menopausal hormone replacement therapy are major factors supporting regional market growth.
• Additionally, expanding access to fertility treatment services across countries such as Germany, France, Italy, and the UK continues to strengthen progesterone demand throughout Europe.
• According to Statista, Germany has one of the largest aging female populations in Europe, with women aged 50 years and above representing a substantial proportion of the population, thereby increasing the addressable market for menopausal hormone therapies.
• Strong public healthcare systems and favorable reimbursement coverage for reproductive health and hormone therapies further support market expansion across the region.

Asia Pacific Progesterone Market

The Asia Pacific progesterone industry is anticipated to grow at the highest CAGR of approximately 10.1% during the forecast period.

• The growth is primarily attributed to rising infertility rates, delayed pregnancies, increasing awareness regarding women’s hormonal health, and rapid expansion of fertility clinics across countries such as China, India, Japan, and South Korea.
• Additionally, increasing healthcare expenditure, improving access to reproductive healthcare services, and growing diagnosis of hormonal disorders are significantly supporting regional market growth.
• According to the World Health Organization (WHO, infertility affects a substantial proportion of reproductive-age individuals globally, with an increasing burden observed across several Asian countries, with India, China, and Indonesia ranking as the top three countries for infertility cases.
• Furthermore, growing adoption of assisted reproductive technologies and increasing demand for bioidentical hormone therapies continue to expand the regional patient pool for progesterone therapies.

Latin America Progesterone Market

The Latin America progesterone industry is experiencing robust growth over the analysis timeframe.

• Countries such as Brazil and Mexico are witnessing increasing investments in women’s healthcare services, fertility treatment infrastructure, and maternal care programs. Expanding access to gynecological consultations and reproductive health services is driving higher demand for progesterone therapies across the region.
• In addition, the rising prevalence of infertility, delayed pregnancies, obesity, and hormonal disorders is increasing the need for progesterone-based treatments in fertility support and hormone replacement therapy applications.
• The region is also experiencing growing adoption of assisted reproductive technologies (ART) and IVF procedures, particularly in urban healthcare centers and private fertility clinics. This is significantly increasing the use of oral, injectable, and vaginal progesterone formulations.
• Furthermore, improving awareness regarding menopause management and bioidentical hormone therapies, along with expanding availability of affordable generic progesterone products, continues to support steady market growth across Latin America.

Middle East & Africa Progesterone Market

The Middle East & Africa (MEA) progesterone industry is experiencing notable growth over the analysis timeframe.

• Countries such as Saudi Arabia, the UAE, and South Africa are increasingly investing in healthcare infrastructure, fertility clinics, and specialized women’s health centers. The expansion of advanced gynecology and reproductive medicine services is contributing to rising progesterone therapy adoption across the region.
• Increasing infertility rates, high prevalence of polycystic ovary syndrome (PCOS), obesity-related hormonal disorders, and delayed pregnancies are further driving demand for progesterone products in fertility and pregnancy support applications.
• The Middle East is also emerging as a regional hub for advanced fertility treatments and IVF services, particularly in the UAE and Saudi Arabia. Growing volumes of assisted reproductive procedures are supporting increased progesterone utilization for luteal phase support and embryo implantation therapies.
• Additionally, improving awareness regarding hormone replacement therapy, increasing healthcare expenditure, and rising access to prescription hormonal therapies are expected to further strengthen market growth throughout the Middle East & Africa region.

Progesterone Market Share

The global cephalosporin drugs market is highly competitive and fragmented, with competition driven by the strong presence of multinational pharmaceutical companies, regional generic manufacturers, and injectable antibiotic suppliers. Top companies including Pfizer, Abbott Laboratories, Lupin Limited, Aurobindo Pharma, and Fresenius Kabi maintain strong market positions through extensive portfolios of oral and injectable cephalosporin products across hospital and retail channels with a combined market share of ~xx%.

Market participants are primarily competing based on pricing, spectrum of antibacterial activity, hospital supply contracts, manufacturing scale, and regulatory approvals for advanced-generation cephalosporins. Manufacturers are increasingly focusing on the development of higher-generation cephalosporins and combination antibiotics capable of addressing multidrug-resistant bacterial infections, particularly resistant Gram-negative pathogens commonly associated with hospital-acquired infections. In addition, growing demand for sterile injectable antibiotics has encouraged companies to expand parenteral manufacturing facilities and strengthen supply chain capabilities to ensure uninterrupted hospital supply.

Progesterone Market Companies

A few of the prominent players operating in the progesterone industry include:

• Abbvie
• Alkem Laboratories
• Bayer AG
• Besins Healthcare
• Cipla
• Ferring Pharmaceuticals
• Glenmark Pharmaceuticals
• Gedeon Richter
• Lupin Limited
• Merck & Co.
• Organon
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• TherapeuticsMD
• Viatris (Mylan)
• Xiromed
• Zydus Lifesciences
• Pfizer

Pfizer is a notable player in the progesterone market through its women’s health and hormone therapy portfolio. The company’s strong global pharmaceutical distribution network and established presence in women’s healthcare continue to support its position in the market.

• AbbVie

Abbvie is an important participant in the progesterone market through its commercialization of Crinone, a progesterone vaginal gel widely used for progesterone supplementation in assisted reproductive technology (ART) and infertility treatments. The company strengthened its presence in women’s health following the acquisition of Allergan, which expanded its portfolio of reproductive and hormone-related therapies.

• Ferring Pharmaceuticals

Ferring Pharmaceuticals is a key player in the progesterone market with a strong focus on reproductive medicine and fertility treatments. The company offers progesterone-based therapies such as Endometrin and Cyclogest for luteal phase support and assisted reproductive technology (ART), strengthening its presence in the global women’s health market.

Progesterone Industry News:

• In August 2025, Gedeon Richter UK launched Nalvee (10 mg dydrogesterone) in UK, reintroducing a dydrogesterone-only hormone replacement therapy (HRT) option after more than 17 years. The oral tablet provides clinicians with an additional progestogen therapy choice for non-hysterectomised women receiving oestrogen therapy and supports more personalized menopause management approaches.
• In September 2025, Xiromed LLC launched Progesterone Vaginal Insert 100 mg, the first FDA-approved generic version of Endometrin. The product received a Competitive Generic Therapy (CGT) designation from the U.S. Food and Drug Administration (FDA), qualifying it for 180 days of market exclusivity under the CGT program. The launch is expected to improve access to affordable progesterone therapies used in assisted reproductive technology (ART) and fertility treatments.
• In May 2022, Xiromed LLC, generic division of Insud Pharma, launched progesterone injection USP, 500 mg/10 mL (50 mg/mL) multiple-dose vial, generic to progesterone injection USP, 50 mg/mL. This helped the company expand its products offerings and attract more customers.
• In November 2021, Fuji Pharma Co., Ltd. launched F-meno capsule 100mg, a natural progestogen drug, in Japan. F-meno is the first drug in Japan indicated for the prevention of endometrial hyperplasia. This launch helped the company to increase its customer base in the country.

The progesterone market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Formulation

• Natural
• Synthetic

Market, By Route of Administration

• Injectable
• Oral
• Transdermal
• Other routes of administration

Market, By Application

• Menopause
• Contraception
• Dysfunctional uterine bleeding
• Hyperplastic precursor lesions
• Endometrial cancer
• Other applications

Market, By Drug Type

• Branded
• Generic

Market, By Type

• Prescription
• OTC

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE